Emicizumab Prophylaxis in Hemophilia A with Inhibitors. In: New England Journal of Medicine. 377. Jahrgang, Nr.377, 2017, S.809–818, doi:10.1056/NEJMoa1703068 (englisch).
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. In: New England Journal of Medicine. 374. Jahrgang, Nr.21, 2016, S.2044–53, doi:10.1056/NEJMoa1511769, PMID 27223146 (englisch).
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. In: Thrombosis and Haemostasis. Nr.7, 2017, S.1348–1357, doi:10.1160/TH17-01-0030, PMID 28451690 (englisch).
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato et alia: Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A N Engl J Med 2016; 374:2044-2053May 26, 2016, doi:10.1056/NEJMoa1511769
Young G: Oral Communication Session, OC 24.1 Hemorrhagic Disorders: Pediatric Aspects, 10. Juli 2017, ISTH 2017, doi: 10.1002/rth2.12012
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. In: New England Journal of Medicine. 379. Jahrgang, Nr.379, 2018, S.811–822, doi:10.1056/NEJMoa1803550 (englisch).
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. In: Lancet Haematol. 6. Jahrgang, Nr.6, 2019, S.e295-e305, doi:10.1016/S2352-3026(19)30054-7 (englisch).
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. In: blood. 134. Jahrgang, Nr.24, 2019, S.2127–2138, doi:10.1182/blood.2019001869 (englisch).
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. In: blood. 137. Jahrgang, Nr.16, 2021, S.2231–2242, doi:10.1182/blood.2020009217 (englisch).
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. In: New England Journal of Medicine. 374. Jahrgang, Nr.21, 2016, S.2044–53, doi:10.1056/NEJMoa1511769, PMID 27223146 (englisch).
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. In: Thrombosis and Haemostasis. Nr.7, 2017, S.1348–1357, doi:10.1160/TH17-01-0030, PMID 28451690 (englisch).